Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Immunocore Holdings plcNASDAQ: IMCR

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 99.6%

Gross margin was 99.6% in Q1 FY2026, up 0.5 pp from a year earlier. On a trailing-twelve-month basis it was 98.8%, down 0.2 pp year over year. Over 3 fiscal years it widened by 1.6 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
99.6%+3.0 pp QoQ
Last fiscal yearDec 2025
97.9%+0.1 pp YoY
LTMMar 2026
98.8%-0.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.5 pp——
1 year+0.1 pp——
3 years+1.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
97.9%
Year-over-year change
+0.1pp

Gross Margin vs competitors

How IMCR compares with its peers on the latest reported figures

  • IMCR's LTM Mar 2026 gross margin of 98.8% is the 3rd highest of the 11 companies compared; the peer median is 79.4%.
  • Its year-over-year change of -0.2 pp is the 7th highest of 11, against a peer median of +0.0 pp.
  • Over three fiscal years its change of +1.6 pp compares with a peer median of -2.4 pp.
IMCR Competitors Peer median
Gross Margin for IMCR and competitors
Company Period LTM level YoY 3-year change
IMTXImmatics N.V.LTM Mar 2026100.0% +0.1 pp+61.8 pp
IPHAInnate Pharma S.A.FY2025100.0% +0.0 pp+89.6 pp
IMCRImmunocore Holdings plcLTM Mar 202698.8% -0.2 pp+1.6 pp
IBRXImmunityBio, Inc.LTM Sep 202696.7% +1.9 pp-0.7 pp
RCUSArcus Biosciences, Inc.LTM Jun 202694.0% -6.0 pp-4.0 pp
CGENCompugen Ltd.LTM Mar 202688.1% +17.9 pp+0.3 pp
BNTXBioNTech SELTM Jun 202670.8% -8.9 pp-5.1 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
JANXJanux Therapeutics, Inc.LTM Mar 202654.1% +476.2 pp-10.5 pp
XNCRXencor, Inc.LTM Jun 202643.3% -18.0 pp+112.9 pp
IMMPImmutep LimitedFY2025-1117.6% -136.1 pp-6.4 pp
Peer median (excluding IMCR) 79.4%+0.0 pp-2.4 pp

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue27.04M144.23M197.39M247.98M297.57M
Cost of Revenue05.29M820.63K5.54M6.21M
Gross Profit27.04M138.94M196.57M242.44M291.36M
Gross Margin100.0%96.3%99.6%97.8%97.9%
Research & Development74.31M84.31M129.42M177.44M204.47M
Selling, General & Admin82.15M0114.35M121.17M120.62M
Operating Expenses156.46M181.71M243.77M298.77M325.09M
Depreciation & Amortization5.63M4.41M3.24M3.36M2.43M
EBITDA(123.58M)(38.35M)(40.87M)(38.5M)387.18K
EBITDA Margin-457.0%-26.6%-20.7%-15.5%0.1%
Operating Income(129.42M)(42.77M)(47.2M)(56.28M)(33.74M)
Operating Margin-478.5%-29.7%-23.9%-22.7%-11.3%
Interest Income65K3.76M14.23M25.62M16.48M
Interest Expense5.57M5.41M4.08M18.84M12.17M
Other Income / Expenses(3.92M)8.95M(982.07K)14.01M19.53M
Income Before Tax(133.34M)(33.82M)(48.19M)(42.32M)(14.21M)
Pre-Tax Margin-493.0%-23.4%-24.4%-17.1%-4.8%
Income Tax Expense111.19K9.65M(4.43M)(1.48M)12.21M
Net Income(133.45M)(43.46M)(43.75M)(40.81M)(26.42M)
Net Margin-493.4%-30.1%-22.2%-16.5%-8.9%
EPS (Basic)(3.13)(0.95)(0.89)(1.02)(0.53)
EPS (Diluted)(3.00)(0.95)(0.89)(1.02)(0.53)
Weighted Avg Shares42.49M45.71M48.89M49.99M50.35M
Weighted Avg Shares (Diluted)43.86M45.71M48.89M49.99M50.35M

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.